PRS51 Comparison of Treatment Satisfaction in Patients with Asthma Taking Leukotriene Modifiers Verus Those Taking Inhaled Corticosteroids  by Tomaszewski, E.L. et al.
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A375
Respiratory symptoms are common among adults living in Russian cities, which may 
indicate high COPD incidence. Awareness of COPD in Russia is lacking. A high propor-
tion of adults aged 40 and older in Russia report frequent respiratory symptoms, and 
these symptoms are associated with significantly worse health status.
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Objectives: COPD is a chronic lung disease that has a detrimental effect upon 
patient’s quality of life. The COPD Assessment Tool (CAT) has been developed 
to measure the impact of the disease. This research explores the relationship 
between the disease-specific CAT, and the general health related utility measure 
EQ-5D. MethOds: COPD is a chronic lung disease that has a detrimental effect 
upon patient’s quality of life. The COPD Assessment Tool (CAT) has been developed 
to measure the impact of the disease. This research explores the relationship 
between the disease-specific CAT, and the general health related utility meas-
ure EQ-5D. Results: A scatter plot relating CAT score to EQ-5D showed that the 
relationship is non-linear. Variance of the EQ-5D score increased with CAT score, 
suggesting the increasing influence of confounding factors for patients report-
ing a higher CAT score (CAT score range variance: 0-10: 0.013, 11-20: 0.026, 21-30: 
0.050 and 31-40: 0.126). A generalized linear model was used to account for the 
non-linear relationship, and control for confounding influences of age, gender, 
physician-perceived COPD severity and number of concomitant conditions, with 
no assumption of constant variance. The relationship between CAT and reversed 
EQ-5D was positive and significant (coefficient 0.070, p-value < 0.0001), illustrating 
higher CAT score was associated with lower EQ-5D. A one point increase in CAT 
score resulted in an approximate 7.2% relative decrease in EQ-5D score. Similarly, 
significant (p-value < 0.0001) negative relationships observed for older patients 
(coefficient 0.016), female gender (coefficient 0.147), greater severity (coefficient 
0.469), and a higher number of comorbidities (coefficient 0.070). cOnclusiOns: 
Increasing COPD impact as measured by the CAT was associated with lower EQ-5D 
scores. However, the increasing variance of EQ-5D for patients with higher CAT 
scores demonstrates the need for both COPD impact and overall health status 
assessment.
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Objectives: Previous research has indicated a strong relationship between 
asthma symptoms and asthma-specific quality of life (QoL). However, past meas-
ures of asthma-specific QoL typically confound symptoms and functional impair-
ment with QoL, which in turn may cause a misleadingly high inter-correlation. 
The current research uses a newly developed measure of asthma-specific QoL 
(the RAND-Impact of Asthma on Quality of Life; RAND-IAQL) that controls for 
asthma symptoms and functional impairment while assessing the degree of 
asthma impact or burden. Using this new measure, we model the relationship 
between asthma specific quality of life, generic quality of life, asthma control, 
and comorbid conditions commonly associated with asthma. MethOds: Using 
a diverse sample of adults with asthma (N= 2032), we use structural equation 
models (SEM) to establish the relationships and suppression effects of asthma 
control, symptoms, comorbidities (e.g., COPD, Sinusitis), and multiple PROMIS QoL 
instruments (including anxiety and social QoL) on the prediction of asthma-
specific QoL. SEM models will be presented sequentially in order to evaluate the 
relative utility of increasingly complex models using likelihood ratio tests and 
changes in the amount of IAQL variance that is accounted for by each added 
predictor (latent) variable. Results: Close fitting SEM models suggest that 
“interference” caused by asthma, an indicator commonly used to measure asthma 
control, is most strongly related to asthma-specific QoL. Contrary to the research 
literature, symptoms of asthma (including shortness of breath, wheezing, and 
cough) and comorbid diseases are less strongly related to asthma specific QoL 
than are general assessments of interference and generic measures of anxiety 
and limitations in social functioning. cOnclusiOns: Asthma-specific QoL is best 
understood as the degree to which asthma impacts or burdens ones daily life. 
While asthma symptoms, control, and general QoL are highly inter-correlated, 
asthma control (primarily interference) is differentially predictive of asthma-
specific QoL.
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Objectives: In response to recommendations from the 2010 NHLBI Asthma 
Outcomes Workshop, we developed a new system for measuring the impact of 
asthma on quality of life (QoL) that avoids confounding QoL with asthma symp-
tomatology and functional impairment. This presentation summarizes the process 
of developing and validating an item bank and short-forms that measure patients’ 
perceptions of the impact or bother of asthma on their life. MethOds: Focus 
groups, supplemented by literature review and expert panel recommendations 
were used to identify key QoL dimensions and develop a pool of items which were 
refined based on cognitive interviews. Items were field-tested using a diverse 
national sample of adults with asthma (N= 2032). Modern measurement theory 
was used to develop an item bank and short forms. We validated our short-forms 
against the Marks AQLQ; ACT; and generic QoL measures. Discriminant validity 
was examined by evaluating scores from respondents who differed according 
one study. cOnclusiOns: Our review showed that PROs are often included in COPD 
product labels in Europe and in the USA. Although the FDA and the EMA agree on a 
general level, the FDA seems more restrictive in the label wording.
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Objectives: To assess the relationship between the questionary of quality of life 
“COPD assessment test” (CAT) and clinical, functional and comorbidity parameters 
and compare patient perceptions of symptoms with that of their family mem-
bers. MethOds: We analysed demographic (age, sex, BMI), lung function (FEV1%) 
and comorbidity variables (Charlson index) in patients with stable COPD. Patients 
and family members independently completed the CAT (family members reported 
their observations of the patient). Results: We included 70 patients (83% men, 
mean age 72±9.4 years, BMI 27.8±4.2 kg/m2, Charlson index (ChI) 2.41±1.7, mean 
FEV1% 57.1±15.1%. Air flow limitation (GOLD): 7 patients (9%) mild, 36 (53%) moder-
ate, 24 (34%) severe and 3 (4%) very severe. There was a significant negative cor-
relation between CAT and FEV1% (r= -0.265, p< 0.0028) but no correlation between 
CAT and ChI, age or BMI. A comparison of CAT scores between the patients and 
their family members showed that 61% of the patients underestimated and 33% 
overestimated their symptoms (CAT scores: 15.5±7.9 (patient) vs. 17.1±7.7 (family) 
(p< 0.038); correlation: (r= 0.72; p< 0.001). We observed correlations in the 8 CAT items. 
We found significant differences between the patients and their family members 
in items 1: coughing (p< 0.015), 3: chest tightness (p< 0.005) and 6: confidence leav-
ing home (p< 0,015) and in overall score (p< 0.038). cOnclusiOns: 1. We found 
a negative correlation between the CAT and FEV1but not between the CAT and 
Charlson index. 2. Patients underestimate their symptoms. Cough, chest tightness 
and confidence leaving home are the issues items that had the greatest discrepancy 
between patients and family members.
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Objectives: To assess treatment satisfaction between patients with self-reported 
asthma for two classes of asthma treatments, leukotriene modifiers (LM group) 
and inhaled corticosteroids (IC group), using a novel patient community in the 
U.S. MethOds: Participants were identified via MediGuard, a digital patient plat-
form where patients enroll online to be part of a digital patient community. All 
information was obtained through participant self-report. Patients were invited 
to complete the Treatment Satisfaction Questionnaire for Medication (TSQM), a 
patient reported outcome (PRO) instrument, at random time points between 2009 
and 2011. Domain scores of the TSQM were compared between the IC and LM 
groups using regression analyses, adjusting for age, gender, self-reported severity 
and number of co-medications. Results: A total of 736 patients were included 
for the IC group, and 647 for LM group. Average ages were comparable (56.3 years 
(SD= 13.8) for IC; 54.9 (13.5) for LM). Both groups were predominantly female (76.3% 
IC; 83.2%, LM). Effectiveness domain scores were similar between IC and LM groups 
(p= 0.502). LM users reported significantly higher scores (i.e., increased satisfaction) 
for other domains: side effects (97.1 (SD= 0.8) vs. 93.5 (0.7), resp.); convenience (89.2 
(0.8) vs. 81.6 (0.7), resp.); global satisfaction (72.3 (1.1) vs. 67.3 (1.0). cOnclusiOns: 
Patients in the LM group reported higher satisfaction in the convenience and global 
satisfaction domains than the IC group. Patients in the LM group reported less 
interference with side effects than the IC group. Providing patients with informa-
tion on population-based satisfaction scores for these two medications could help 
inform patients’ treatment selection decisions.
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Objectives: Chronic obstructive pulmonary disease (COPD) is a major cause of dis-
ability worldwide, but awareness of COPD and information regarding the burden of 
this disease are lacking worldwide, including Russia. The aim of the current study 
was to assess the prevalence of COPD symptoms (cough with mucous, wheezing, and 
shortness of breath) among a representative sample of adults aged 40 and above in 
major cities in Russia. MethOds: Data was obtained from the 2011 Russia National 
Health and Wellness Survey, a cross-sectional survey of the adult population in the 
city adult population in Russia which includes information on awareness, experi-
ence, and diagnosis of medical conditions, health care-related attitudes, demographic 
characteristics, and health outcomes. The frequency of COPD symptoms was assessed 
using the Lung Function Questionnaire, and health status was assessed using the 
SF-12v2. Those experiencing a symptom at least ‘sometimes’ were compared to 
those who experienced the symptom ‘rarely’ or less using independent-samples 
t-tests. Results: A total of 5920 adults aged 40 and older completed the survey. After 
weighting, 45%, 27%, and 18% reported shortness of breath, coughing up mucous, and 
wheezing, respectively, and 54% reported at least one symptom. Only 23% of those 
surveyed were aware of COPD; awareness of COPD was greatest among those with the 
most symptoms but even among those with all three symptoms, only 31% were aware 
of the condition. Experience of each symptom was associated with worse mental 
and physical component summary scores on the SF-12v2, with decrements ranging 
from 2-6 points depending on the symptom and score considered. cOnclusiOns: 
